Latest News: CBS Corporation (NYSE:CBS), VirnetX Holding Corp (NYSEMKT:VHC), Potash Corporation of Saskatchewan Inc. (NYSE:POT), Amgen Inc. (NASDAQ:AMGN), NanoViricides (NYSEMKT:NNVC)


CBS Corporation (NYSE:CBS) shares advanced 1.17% in last trading session and ended the day at $45.79. CBS Gross Margin is 40.30% and its has a return on assets of 11.70%. CBS Corporation (NYSE:CBS) quarterly performance is -25.36%.

CBS Corporation (NYSE:CBS) is a mass media company. The Company operates through segments, including Entertainment, Cable Networks, Publishing and Local Broadcasting. The Entertainment segment is composed of the CBS Television Network, CBS Television Studios, CBS Global Distribution Group, CBS Interactive and CBS Films. The Cable Networks segment is composed of Showtime Networks, which operates program services, such as Showtime, The Movie Channel, and Flix; CBS Sports Network, and Smithsonian Networks, which operates a program service, Smithsonian Channel.

CBS Corporation (NYSE:CBS) has announced a new affiliation agreement with station group Tegna Media (formerly Gannett), bringing 10 network affiliates covering 10 million U.S. households into its CBS All Access OTT service. The agreement covers CBS affiliates in Washington, D.C., Houston, San Antonio, New Orleans, Tampa, Fla., Greensboro, N.C., Little Rock, Ark., Columbia, S.C., Macon, Ga. and Spokane, Wash.

VirnetX Holding Corp (NYSEMKT:VHC) ended the last trading day at $3.48. Company weekly volatility is calculated as 11.77% and price to cash ratio as 6.51. VirnetX Holding Corp (NYSEMKT:VHC) showed a weekly performance of 6.42%.

VirnetX Holding Corporation (NYSEMKT:VHC) is an Internet security software and technology Company with patented technology for secure communications including 4G LTE security. The Company’s software and technology solutions, including its secure domain name registry and GABRIEL Connection Technology, are designed to facilitate secure communications and provide the security platform required by Internet-based applications, such as instant messaging (IM), voice over Internet protocol (VoIP), mobile services, streaming video, file transfer, remote desktop and machine-to-machine (M2M) communications.

VirnetX Holding Corp (NYSEMKT:VHC) on August 21, 2015, announced that it has filed a universal shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”). The universal shelf registration statement is intended to provide the Company with the flexibility to offer and sell from time to time up to $100 million of equity, debt or other types of securities described in the registration statement, or any combination of such securities.

On 28 August, Potash Corporation of Saskatchewan Inc. (NYSE:POT) shares increased 0.70% and was closed at $25.95. POT EPS growth in last 5 year was 11.00%. Potash Corporation of Saskatchewan Inc. (NYSE:POT) year to date (YTD) performance is -23.99%.

Potash Corporation of Saskatchewan Inc. (NYSE:POT) is a fertilizer company. The Company operates in three business segments: potash, nitrogen and phosphate. The Company owns and operates five potash operations in Saskatchewan and one in New Brunswick. Its nitrogen operations involve the production of nitrogen fertilizers and nitrogen feed and industrial products, including ammonia, urea, nitrogen solutions, ammonium nitrate and nitric acid. It has nitrogen facilities in Georgia, Louisiana, Ohio and Trinidad.

Potash Corporation of Saskatchewan Inc. (NYSE:POT) was downgraded by Zacks
from a “hold” rating to a “sell” rating in a note issued to investors. According to Zacks, “Potash Corp.’s profit fell in the second quarter of 2015, hurt by lower nitrogen prices. Earnings trailed the Zacks Consensus Estimate whiles sales beat expectations.

Amgen Inc. (NASDAQ:AMGN) shares advanced 0.11% in last trading session and ended the day at $155.89. AMGN Gross Margin is 79.90% and its has a return on assets of 8.30%. Amgen Inc. (NASDAQ:AMGN) quarterly performance is -0.26%.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet.

Amgen Inc. (NASDAQ:AMGN) has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that have been used for decades. The drug Repatha could eventually help millions of Americans who face increased risks of heart disease because they cannot control their cholesterol with existing drugs and methods. But concerns about the medication’s price tag — $14,100 per year — and long-term benefits will likely limit its use in the near-term.

NanoViricides, Inc. (NYSEMKT:NNVC) caters to the Healthcare space. Its weekly performance is -8.13%. On the last day of trading company shares ended up $1.13. NanoViricides, Inc. (NYSEMKT:NNVC) distance from 50-day simple moving average (SMA50) is -24.78%.

NanoViricides, Inc. (NYSEMKT:NNVC) is a development-stage company. The Company is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. The Company has several drugs in various stages of early development. The Company’s drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (TheraCour), to which the Company has exclusive licenses in perpetuity for the treatment human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies.

On 17 August, NanoViricides, Inc., (NYSEMKT:NNVC) reported that it is accelerating its HerpeCide™ drug development program. The Company will continue to develop its anti-herpesvirus franchise in parallel with the development of FluCide™, its anti-influenza drug candidate. The Company believes that drug development of the external treatments for the different herpes virus infections, such as topical skin creams or lotions for the treatment of herpes lesions, or shingles rash, as well as eye drops or gels for the treatment of herpes keratitis, are likely to require significantly less development work compared to the development of an injectable drug.


Leave a Reply

Your email address will not be published. Required fields are marked *